Analysis of glioblastoma-metabolism by MRI-Spectroscopy
- Conditions
- C71.9Brain, unspecified
- Registration Number
- DRKS00014760
- Lead Sponsor
- Abt. Neurochirurgie UKSH Kiel
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 44
Inclusion Criteria
Intracranial tumors
Exclusion Criteria
in need of protection (children)
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Minimum 10 patients should be examinated with MRS (magnetic resonance spectroscopy). The results of edge and central regions of the tumor will be compared.
- Secondary Outcome Measures
Name Time Method The data-research is to be continued for about three years.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms does MRI-Spectroscopy reveal in C71.9 glioblastoma metabolism?
How does DRKS00014760 compare to standard-of-care in glioblastoma patient outcomes?
What biomarkers correlate with metabolic profiles in UKSH Kiel glioblastoma studies?
Are there adverse events associated with MRI-Spectroscopy in brain tumor analysis?
What drug targets are identified through metabolic imaging in GBM research?